• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 18, 2019
Company Drug/Device Medical Condition Status
ADC Therapeutics ADCT-402 (loncastuximab tesirine) plus AstraZeneca's IMFINZI (durvalumab) advanced diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL) Phase I trial initiated enrolling 75 subjects
Exelixis, Inc. XL092 cancer Phase I trial initiated
ReGenTree, LLC and Ora, Inc. RGN-259 dry eye syndrome Phase III trial initiated enrolling 700 subjects
LASEROPTEK Co., Ltd. PicoLO picosecond Nd:YAG laser dermatology and general and plastic surgery 510(k) clearance granted by the FDA
Grifols, S.A. Procleix Babesia assay blood screening 510(k) clearance granted by the FDA
Finch Therapeutics Group, Inc. CP101 recurrent Clostridium difficile (C. difficile) infection Breakthrough Therapy designation granted by the FDA
RDD Pharma, Inc. RDD-0315 fecal incontinence in spinal cord injury Fast Track designation granted by the FDA
Neurotech Pharmaceuticals, Inc. NT-501 (Renexus) macular telangiectasia type 2 (MacTel) Fast Track designation granted by the FDA
IntraBio, Inc. IB1001 GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) IND approval granted by the FDA
Pulmatrix, Inc. Pulmazole (PUR1900) allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma IND approval granted by the FDA
Precigen, Inc. PRGN-3005 advanced-stage platinum-resistant ovarian cancer IND approval granted by the FDA
Janssen Pharmaceutical Companies of Johnson & Johnson Darzalex (daratumumab) split-dosing regimen multiple myeloma BLA approval granted by the FDA
Sanofi Cablivi (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression acquired thrombotic thrombocytopenic purpura (aTTP) in adults BLA approval granted by the FDA
Medtronic expanded indication for Pipeline Flex embolization device brain aneurysm Approval granted by the FDA
Orthofix Medical, Inc. M6-C artificial cervical disc cervical disc degeneration Approval granted by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing